Monotherapy in diabetes management is losing interest due to its ineffectiveness in achieving optimal glycaemic control in a significant proportion of diabetic patients. Therefore, combined therapy is increasingly preferred by clinicians, which offers enhanced effectiveness and a better safety profile for managing the condition. The present work deals with the designing of a dual drug nanocarrier based on MCM-48 and 12-tungtophosphoric acid (TPA) for the co-delivery of Glipizide (GLP) and Metformin Hydrochloride (MTF) as well as its characterization using various techniques. An release study was carried out at two different pHs (pH 1.2 and pH 7.4) at 37 °C under stirring conditions which was further supported by an dissolution study carried out using a USP Type II dissolution apparatus. The obtained results were compared with that of the marketed available formulation, Glirum-MF, and the designed nanocarrier showed a better controlled release of both the drugs in comparison with the conventional drug. Additionally, considering the anticancer properties of both the drugs, MTT assay indicated that the carrier is non-toxic while the drug loaded nanocarrier shows apoptosis against HepG2 cells.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883462 | PMC |
| http://dx.doi.org/10.1039/d5ra00204d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.
J Adv Res
March 2025
Department of Orthopaedics, Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038 Shaanxi, China. Electronic address:
Introduction: Bone fracture is increasing in patients with type 2 diabetes mellitus (T2DM) due to skeletal fragility. Most antidiabetics are expected to reduce the incidence of fracture in patients with T2DM, however the results are disappointing. Metformin and GLP-1 receptor agonists have a neutral or minor positive effect in reducing fractures.
View Article and Find Full Text PDFThe antitumor effects of metformin are potentially mediated through LPA receptor inhibition.
Diabetes Res Clin Pract
March 2025
Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan; Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan. Electronic address:
Aims: Although metformin has antitumor effects, the detailed mechanism of action, particularly with respect to the cellular responses mediated through G protein-coupled receptors (GPCRs), remains unclear.
Methods And Results: Here, we assayed a panel of 200 GPCRs in cells treated with metformin and reported that signaling through several receptors, including lysophosphatidic acid (LPA) receptors, was suppressed. Metformin significantly attenuated LPA-induced intracellular Ca mobilization in LPA receptor 1 (LPAR1)-, 2 (LPAR2)-, and 3 (LPAR3)-transfected rat hepatoma RH7777 cells.
Effect of Metformin Exposure in Gestational Diabetes Mellitus on Infant Mesenchymal Stem Cell Metabolism.
Am J Physiol Endocrinol Metab
March 2025
Department of Kinesiology, East Carolina University, Greenville, North Carolina, United States.
Offspring exposed to metformin treatment for gestational diabetes mellitus (GDM) experience altered growth patterns that increase the risk for developing cardiometabolic diseases later in life. The adaptive cellular mechanisms underlying these patterns remain unclear. Therefore, the objective of this study was to determine if chronic metformin exposure associated with GDM treatment elicits infant cellular metabolic adaptations.
View Article and Find Full Text PDFNeuroprotective Effects of Metformin in Stroke Patients: A Systematic Review and Meta-analysis of Cohort Studies.
Clin Neuropharmacol
March 2025
Department of Neurology, Firoozgar Hospital, School of Medicine, Iran University of Medical Science, Fasa, Iran.
Objectives: People with diabetes are 1.5 times more likely to experience stroke than those without diabetes, underlining the urgent need to address this issue. Metformin is often the initial medication chosen to manage diabetes mellitus (DM).
View Article and Find Full Text PDFAmniotic membrane hydrogel as novel injectable platform in combination with metformin for treatment of sciatic nerve injury.
J Appl Biomater Funct Mater
March 2025
Kerman Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Peripheral nerve tissue engineering is a field that uses cells, growth factors and biological scaffold material to provide a nutritional and physical support in the repair of nerve injuries. The specific properties of injectable human amniotic membrane-derived hydrogel including growth factors as well as anti-inflammatory and neuroprotective agents make it an ideal tool for nerve tissue repair, and metformin may also aid in nerve regeneration. The aim of this study was to investigate the effects of hydrogel derived from amniotic membrane (AM) along with metformin (MET) administration in the repair of sciatic nerve injury in male rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!